Due to the widespread existence of sEH in the human body, its metabolic pathway is involved in many diseases, including ischemic stroke, hypertension, heart disease, kidney disease, etc. In theory, the development of drugs that inhibit sEH would seem to reverse or treat the disease. The gene discussed is EPHX2; the disease is kidney disorder.